Scancell Holdings Plc · LSE:SCLP

Scancell — LSX World Congress 2020

21 slides from Scancell's conference presentation, February 2020

  1. Slide 1: At the Forefront of Immuno-Oncology

    AT THE FOREFRONT OF IMMUNO-ONCOLOGY LSX World Congress, London February 2020 LSE: SCLP.L AT THE FOREFRONT OF IMMUNO-ONCOLOGY

  2. Slide 2: Disclaimer

    DISCLAIMER The information contained in these slides has been prepared by Scancell Holdings plc (the "Company"). It has not been approved by the United Kingdom Financial Conduct Authority under the Prospectus Rules (made under Part VI of the Financial Services and Markets Act 2000) or otherwise, or

  3. Slide 3: Scancell is Operating at the Forefront of Immuno-Oncology

    SCANCELL IS OPERATING AT THE FOREFRONT OF IMMUNO-ONCOLOGY ► Expected to exceed US$100bn p.a. by 2022 (source: ResearchAndMarkets.com 30 November 2018) ► Merck and BMS have developed blockbuster checkpoint inhibitor drugs with sales > US$7bn p.a. THE MARKET ► Checkpoint inhibitors prevent tumour cell

  4. Slide 4: Immuno Oncology Development & Commercial Drivers

    IMMUNO ONCOLOGY DEVELOPMENT & COMMERCIAL DRIVERS „ Innovative platform technologies to generate novel therapeutics „ Validation through translation of core science to clinically relevant data „ Unmet need: response rates and duration of response to checkpoint inhibitors vary greatly depending on the

  5. Slide 5: Development Pipeline

    DEVELOPMENT PIPELINE IMMUNOBODY® MODITOPE® AvidiMab™ / TaG mAbs „ SCIB1: Targets malignant melanoma. Phase 2 „ Modi-1: Phase 1/2 trial including breast, ovarian, „ Anti-glycan mAbs: Monoclonal antibodies trial in patients receiving immune checkpoint renal and head & neck cancer planned for 2H’20 (mA

  6. Slide 6: Scancell's Cancer Vaccine Platforms

    SCANCELL’S CANCER VACCINE PLATFORMS „ Key challenge is to stimulate an effective T cell response to reject or kill the growing tumour „ Most vaccine strategies only stimulate low frequency, low avidity T cell responses that fail to control tumour growth „ Scancell’s novel therapies stimulate high av

  7. Slide 7: The ImmunoBody Platform

    THE IMMUNOBODY® PLATFORM „ Proprietary patent protected platform „ Several cancer associated T cell epitopes are engineered into a human antibody framework to make a genetic antigen/antibody complex SCIB DNA Cancer antigen sequences Vector inserted into variable region of ImmunoBody® „ Novel dual me

  8. Slide 8: SCIB1 in Patients with Late Stage Melanoma

    SCIB1 IN PATIENTS WITH LATE STAGE MELANOMA SCIB1 has an excellent safety profile with no dose-limiting SURVIVAL IN RESECTED PATIENTS toxicities and no serious adverse events related to study drug or delivery device „ Overall survival with SCIB1 treatment superior to historical survival rates TUMOUR

  9. Slide 9: SCIB1 in Late Stage Melanoma Patients

    SCIB1 IN LATE STAGE MELANOMA PATIENTS PATIENTS WITHOUT TUMOUR PRESENT AT STUDY ENTRY Study entry 5 years Disease-free patients Patients with recurrence Deceased patients SCIB1 dose (2/4 mg) Disease recurrence Death Surgery Radiotherapy Electrochemotherapy Ipilimumab Nivolumab Pembrolizumab -60 -50 -

  10. Slide 10: SCIB1 Boosts Immune Checkpoint Therapy

    SCIB1 BOOSTS IMMUNE CHECKPOINT THERAPY IN A MOUSE MELANOMA MODEL, SURVIVAL RATES WERE SIGNIFICANTLY BOOSTED WHEN ANTI-PD-1 THERAPY WAS COMBINED WITH SCIB1 TREATMENT „ Survival rates for SCIB1 ImmunoBody® monotherapy ≈ anti-PD-1 „ Combination therapy resulted in an 85% survival rate „ SCIB1 also upre

  11. Slide 11: SCIB1 + Checkpoint Inhibitor Phase 2 Trial

    SCIB1 + CHECKPOINT INHIBITOR PHASE 2 TRIAL PATIENT POPULATION „ Histologically confirmed, unresectable AJCC stage III or stage IV melanoma „ No prior systemic treatment for advanced disease „ Suitable for treatment with Keytruda (pembrolizumab), with measurable disease „ Part 1 safety run-in (n=6);

  12. Slide 12: The Moditope Platform

    THE MODITOPE® PLATFORM Stress-Induced Post-Translational Modifications (siPTM) ► One such modification involves the process of CITRULLINATION Modi-1 ► The alteration of proteins due to enzymatic conversion of arginine residues to citrulline ► Citrullination occurs as a result of a degradation and ‘r

  13. Slide 13: Moditope Lead Candidate: Modi-1

    MODITOPE® LEAD CANDIDATE: Modi-1 „ Consists of: „ Two citrullinated vimentin peptides (Vim-1 and Vim-2) Conjugated with Amplivant® adjuvant to boost immune response „ One citrullinated enolase peptide (Eno-1) „ Vimentin and enolase targets are highly expressed in triple negative breast cancer (TNBC)

  14. Slide 14: Proposed Modi-1 First in Human Study

    PROPOSED Modi-1 FIRST IN HUMAN STUDY STUDY DESIGN „ Two initial cohorts to explore low and high conjugate doses „ Criteria to expand cohorts: ≥ 30% of patients show an immune response and <2 dose-limiting toxicity (DLT) at selected dose „ Second part of the study will enrol four tumour-specific expa

  15. Slide 15: AvidiMab and MABs Targeting Tumour Associated Glycans

    AvidiMab™ and MABs TARGETING TUMOUR ASSOCIATED GLYCANS (TaG) Glycosylation is a recognised modulator of the malignant phenotype of cancer cells „ 5 anti-glycan mAbs FG88, FG27, FG129, FL134, FG2811 –unique direct cancer targets CAR-T therapy „ Ultraspecific to unique tumour associated glycans (TaG)

  16. Slide 16: AvidiMab Platform

    AvidiMab™ PLATFORM AvidiMab™ Key Features: „ Enhances functional affinity „ Increases direct cell killing „ Improved in vitro and in vivo anti-tumour activity „ Could improve the therapeutic index of any monoclonal antibody „ Patent protected Increases the avidity of human antibodies by promoting no

  17. Slide 17: TaG Antibody Summary

    TaG ANTIBODY SUMMARY mAb FG27 FG88 FG129 FL133/4 FG2811 Glycan target Lewisy Lewisa/c/x Sialyl-di-Lewisa FucGM1 SSEA-4 (ultraspecific) Stimulates stem cell memory (TSCM) Antigen Glycolipids & Glycolipids & Glycoproteins Glycolipid Glycolipid glycoproteins glycoproteins Tumour targets Colorectal, Gas

  18. Slide 18: Highlights for CY19

    HIGHLIGHTS FOR CY19 Operational Financial „ SCIB1 Phase II trial „ MHRA approval and initiation of UK arm of study „ Vulpes investment and Board position „ Modi-1 manufacturing „ In June, Scancell raised gross proceeds of £3.88m by the „ GMP manufacturing and toxicology studies issue of 77.6m new or

  19. Slide 19: Anticipated Newsflow + Milestones

    ANTICIPATED NEWSFLOW + MILESTONES IMMUNOBODY® MODITOPE® SCIB1 Modi-1 „ SCIB1/checkpoint inhibitor Phase 2 study in late „ First-In-Human study with Modi-1 in patients with stage melanoma TNBC, ovarian cancer, renal cancer and HNSCC planned to start 2H CY20 „ Activation of additional study centres in

  20. Slide 20: Outlook

    OUTLOOK 3 PLATFORMS +BROAD PIPELINE+ 5 CORE ACTIVITIES ► Generate meaningful clinical data to address unmet needs: clinical read-outs (SCIB1 CLINICAL DATA Phase 2 & Modi-1 Phase1/2 interim data) anticipated within next 18 months ► Extend utility of Moditope® platform beyond Modi-1 and Modi-2 in asso

  21. Slide 21: Contact

    Contact Dr. Cliff Holloway, CEO Email: cliffholloway@scancell.co.uk AT THE FOREFRONT OF IMMUNO-ONCOLOGY 21 21

Scancell Holdings — LSX World Congress 2020 on 6ix